Autologous vs. Allogeneic CAR-T Therapies
While both allogeneic and autologous therapies use similar technologies common to the growth of cells, the scale is different. Allogeneic therapies are “off the shelf,” and are used to treat many patients (sometimes thousands). More time is available to quality control the product prior to administration. Autologous therapies are “custom” products for each patient and the chain of identity of the patient samples is critical to assure the right product is returned to the patient. Scale up of manufacturing for allogeneic cells is similar to the techniques used to make protein drugs and other large scale cell derived materials while autologous cells require scale out, the production of many individual products at the same time. We’ve curated insightful editorial that concentrates on the advancements of both allogeneic and autologous therapies and how to manufacture them at scale.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.